Hengrui Pharma accelerates bid for global brand status
The Chinese drugmaker has outlined plans for a secondary listing in Hong Kong to raise its international profile and bolster its overseas ambitions Key Takeaways: Hengrui Pharmaceuticals started out producing…
Recent Articles
RELATED ARTICLES
-
Earnings blow for CSPC Pharma as the state drives a hard bargain
1093.HK -
Cash-hungry Mabwell seeks financial tonic from Hong Kong investors
688062.SHG
-
Xuanzhu Biopharm set for spin-off in Hong Kong IPO
0460.HK
- Innogen Pharma jostles for a slice of the weight-loss market
-
CATL leads new charge of Mainland-listed companies into Hong Kong
300750.SHE
-
Baozun returns to the black as Gap expansion accelerates
9991.HK BZUN.US
-
After a failed Fosun buyout, what’s next for drug maker Henlius Biotech?
2696.HK
